Outcomes of spironolactone treatment in patients in Northeast China suffering from heart failure with mid-range ejection fraction

References

• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891-975
   PubMed Web of Science ®Google Scholar
• Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017;19:1574-85
   PubMed Web of Science ®Google Scholar
• Rickenbacher P, Kaufmann BA, Maeder MT, et al. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Eur J Heart Fail 2017;19:1586-96
   PubMed Web of Science ®Google Scholar
• Tsuji K, Sakata Y, Nochioka K, et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study. Eur J Heart Fail 2017;19:1258-69
   PubMed Web of Science ®Google Scholar
• Farmakis D, Simitsis P, Bistola V, et al. Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome. Clin Res Cardiol 2017;106:359-68
   PubMed Web of Science ®Google Scholar
• Bell SP, Adkisson DW, Lawson MA, et al. Antifailure therapy including spironolactone improves left ventricular energy supply-demand relations in nonischemic dilated cardiomyopathy. J Am Heart Assoc 2014;3;pii:e000883
   Web of Science ®Google Scholar
• Vizzardi E, Sciatti E, Bonadei I, et al. Effects of spironolactone on ventricular-arterial coupling in patients with chronic systolic heart failure and mild symptoms. Clin Res Cardiol 2015;104:1078-87
   PubMed Web of Science ®Google Scholar
• Guo L, Guo X, Chang Y, et al. Prevalence and risk factors of heart failure with preserved ejection fraction: a population-based study in Northeast China. Int J Environ Res Public Health 2016;13;pii:E770
   Web of Science ®Google Scholar
• Dong G, Sun Z, Zheng L, et al. Prevalence, awareness, treatment, and control of hypertension in rural adults from Liaoning Province, Northeast China. Hypertens Res. 2007;30:951-8
   PubMed Web of Science ®Google Scholar
• Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-6
   PubMed Web of Science ®Google Scholar
• Parissis JT, Nikolaou M, Farmakis D, et al. Self-assessment of health status is associated with inflammatory activation and predicts long-term outcomes in chronic heart failure. Eur J Heart Fail 2009;11:163-9
   PubMed Web of Science ®Google Scholar
• Rajati F, Feizi A, Tavakol K, et al. Comparative evaluation of health-related quality of life questionnaires in patients with heart failure undergoing cardiac rehabilitation: a psychometric study. Arch Phys Med Rehab 2016;97:1953-62
   PubMed Web of Science ®Google Scholar
• Sullivan MD, Levy WC, Russo JE, et al. Summary health status measures in advanced heart failure: relationship to clinical variables and outcome. J Cardiac Fail 2007;13:560-8
   PubMed Web of Science ®Google Scholar
• Garin O, Ferrer M, Pont A, et al. Evidence on the global measurement model of the Minnesota Living with Heart Failure Questionnaire. Qual Life Res 2013;22:2675-84
   PubMed Web of Science ®Google Scholar
• Bilbao A, Escobar A, Garcia-Perez L, et al. The Minnesota living with heart failure questionnaire: comparison of different factor structures. Health Qual Life Outcomes 2016;14:23
   PubMedGoogle Scholar
• McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847
   PubMed Web of Science ®Google Scholar
• Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009;22:107-33
   PubMed Web of Science ®Google Scholar
• Bland JM, Altman DG. Cronbach’s alpha. BMJ 1997;314:572
   PubMed Web of Science ®Google Scholar
• Li Z, Guo X, Zheng L, et al. Grim status of hypertension in rural China: results from Northeast China Rural Cardiovascular Health Study 2013. J Am Soc Hypertens 2015;9:358-64
   PubMed Web of Science ®Google Scholar
• Capuano A, Scavone C, Vitale C, et al. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF). Int J Cardiol 2015;200:15-19
   PubMed Web of Science ®Google Scholar
• Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383-92
   PubMed Web of Science ®Google Scholar
• Upadhya B, Hundley WG, Brubaker PH, et al. Effect of spironolactone on exercise tolerance and arterial function in older adults with heart failure with preserved ejection fraction. J Am Geriatr Soc 2017:65:2374–82
   Web of Science ®Google Scholar
• Williams L, Onarecker C. Clinical question: in congestive heart failure patients with preserved ejection fraction, does spironolactone improve cardiac outcomes? J Okla State Med Assoc 2016;109:437-8
   PubMedGoogle Scholar
• Shantsila E, Haynes R, Calvert M. IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial. BMJ Open 2016;6:e012241
   Google Scholar
• Kosmala W, Rojek A, Przewlocka-Kosmala M, et al. Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction. J Am Coll Cardiol 2016;68:1823-34
   PubMed Web of Science ®Google Scholar
• Miller RJ, Howlett JG. Evolving role for mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction. Curr Opin Cardiol 2015
   PubMed Web of Science ®Google Scholar
• Cao G, Della Penna SL, Kouyoumdzian NM, et al. Immunohistochemical expression of intrarenal renin angiotensin system components in response to tempol in rats fed a high salt diet. W J Nephrol 2017;6:29-40
   PubMedGoogle Scholar
• Kelly TN, Li C, Hixson JE, et al. Resequencing study identifies rare renin-angiotensin-aldosterone system variants associated with blood pressure salt-sensitivity: the GenSalt study. Am J Hypertens 2017;30:495-501
   PubMed Web of Science ®Google Scholar
• Catena C, Colussi GL, Brosolo G, et al. Salt, aldosterone, and parathyroid hormone: what is the relevance for organ damage? Int J Endocrinol 2017;2017:4397028
   PubMedGoogle Scholar
• Loan Le TY, Mardini M, Howell VM, et al. Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial infarction. Hypertension 2012;59:1164-9
   PubMed Web of Science ®Google Scholar
• Javad Habibi VGD. Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression. Am J Physiol Heart Circ Physiol 2011:1522-39
   Web of Science ®Google Scholar
• Lam CS, Teng TH. Understanding heart failure with mid-range ejection fraction. JACC Heart Fail 2016;4:473-6
   PubMed Web of Science ®Google Scholar